Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma

纤维板层肝细胞癌融合癌蛋白治疗靶向中心

• 批准号: 10221308
• 负责人: SANFORD M SIMON
• 金额: $ 18.91万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10221308
• 关键词: Adolescent and Young Adult; Affect; Age; Antisense Oligonucleotides; Belief; Benchmarking; Biocompatible Materials; Biological Models; Catalytic Domain; Cells; Child; Chimeric Proteins; Communities; Cyclic AMP-Dependent Protein Kinases; DNA; Failure; Fibrolamellar Hepatocellular Carcinoma; Fusion Oncogene Proteins; Genes; Genetic; Genome; Goals; Heat-Shock Response; Human; Individual; Liver; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of liver; Messenger RNA; Molecular Chaperones; Neoplasm Metastasis; Oncoproteins; Operative Surgical Procedures; Organ; PRKACA gene; Pathogenesis; Patients; Pediatric Neoplasm; Population; Primary Neoplasm; Proteins; Proteome; Research Personnel; Somatic Mutation; Testing; Therapeutic; Transcript; Work; combat; design; fusion gene; human genome sequencing; knock-down; multicatalytic endopeptidase complex; patient population; small molecule; targeted treatment; therapeutic development; therapeutic evaluation; therapeutic target; transcriptome; tumor

Project Summary / Abstract Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary tumor in children, adolescents and young adults. The primary tumor is initiated and driven by a single alteration in the DNA: A deletion of ~400kb that results in a fusion gene between the heat shock co-chaperone DNAJB1 and the catalytic subunit of protein kinase A, PRKACA. If the tumor is limited to the liver, then surgery is the accepted therapy. However, if the tumor has metastasized, there is no accepted therapy. This project will determine how the fusion oncoprotein leads to pathogenesis and will develop therapeutics targeted to the fusion oncoprotein. Pathogenesis is being probed by examining what is different about the fusion oncoprotein that causes changes in the cell. Therapeutics will target the fusion oncoprotein through small molecules to block activity, or small molecules to send it to the proteasome, or small molecules for allosteric inhibition.

项目摘要/摘要